Skip to main content Skip to search Skip to main navigation

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Overton is currently deputy director of the White House Domestic Policy Council. Previously, she served as chief policy officer and vice chair of the Center for a Healthy America at AFPI (America First Policy Institute). Before joining AFPI, Overton was a general surgery resident at Johns Hopkins University, where she also obtained a PhD in clinical investigation. 

Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed) said the group supports the nomination. 

“We look forward to continuing our work with FDA under Dr. Overton’s leadership if she is confirmed by the Senate. As a medical doctor with a background in public health, she has a deep understanding of the critical role medical technology plays in lowering cost and improving patient outcomes. The transformative nature of medtech helps ensure that patients are in control of their own health and doctors are empowered to treat patients with the most innovative technologies. It is essential that we continue the progress we have made to ensure that transparency, consistency, and predictability remain the hallmarks of the review process at CDRH.

President Trump wrote on Truth Social: “She is known to take on the HARDEST issues, and bring me solutions that work best for the Country….We need her leadership at the FDA now.”


Source:

FDA: Trump taps Heidi Overton as next FDA Commissioner

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next